| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Alaa El-Sayed El-Sisi, Samia Salem Sokkar, Magda El-Sayed El-Sayad, Ehab Sayed Ramadan, Enass Yossef Osma. Celecoxib and omega-3 fatty acids alone and in combination with risperidone affect the behavior and brain biochemistry in amphetamine-induced model of schizophrenia. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. vol 82. 2017-01-31. PMID:27470381. |
celecoxib and omega-3 fatty acids alone and in combination with risperidone affect the behavior and brain biochemistry in amphetamine-induced model of schizophrenia. |
2017-01-31 |
2023-08-13 |
rat |
| Alaa El-Sayed El-Sisi, Samia Salem Sokkar, Magda El-Sayed El-Sayad, Ehab Sayed Ramadan, Enass Yossef Osma. Celecoxib and omega-3 fatty acids alone and in combination with risperidone affect the behavior and brain biochemistry in amphetamine-induced model of schizophrenia. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. vol 82. 2017-01-31. PMID:27470381. |
in the present study, an amphetamine-induced model of schizophrenia in adult male rats was used to evaluate the effects of celecoxib, omega-3, celecoxib+risperidone and omega-3+ risperidone on the behavior of animals and on brain lipid peroxidation or tumor necrosis factor-alpha. |
2017-01-31 |
2023-08-13 |
rat |
| Reiji Yoshimura, Hikaru Hori, Asuka Katsuki, Kiyokazu Atak. Marked Improvement of Meige Syndrome in a Japanese Male Patient with Schizophrenia After Switching from Risperidone to Paliperidone: A Case Report. Journal of UOEH. vol 38. issue 3. 2017-01-27. PMID:27627971. |
marked improvement of meige syndrome in a japanese male patient with schizophrenia after switching from risperidone to paliperidone: a case report. |
2017-01-27 |
2023-08-13 |
Not clear |
| Aurigena Antunes de Araújo, Susana Barbosa Ribeiro, Ana Cely Souza Dos Santos, Telma Maria Araújo Moura Lemos, Caroline Addison Xavier Medeiros, Gerlane Coelho Bernardo Guerra, Raimundo Fernandes de Araújo Júnior, Antoni Serrano-Blanco, Maria Rubio-Valer. Quality of Life and Hormonal, Biochemical, and Anthropometric Profile Between Olanzapine and Risperidone Users. The Psychiatric quarterly. vol 87. issue 2. 2017-01-09. PMID:26220635. |
this cross-sectional study compared quality of life and side effects in 108 users of olanzapine or risperidone suffering schizophrenia and being attended at psychiatric ambulatory services in rio grande do norte, brazil. |
2017-01-09 |
2023-08-13 |
Not clear |
| Jasem Y Al-Hashel, Ismail Ibrahim Ismail, John K John, Mohammed Ibrahim, Mahmoud Al. Worsening of myasthenia gravis after administration of injectable long-acting risperidone for treatment of schizophrenia; first case report and a call for caution. Neuromuscular disorders : NMD. vol 26. issue 4-5. 2017-01-03. PMID:27012182. |
worsening of myasthenia gravis after administration of injectable long-acting risperidone for treatment of schizophrenia; first case report and a call for caution. |
2017-01-03 |
2023-08-13 |
Not clear |
| Jasem Y Al-Hashel, Ismail Ibrahim Ismail, John K John, Mohammed Ibrahim, Mahmoud Al. Worsening of myasthenia gravis after administration of injectable long-acting risperidone for treatment of schizophrenia; first case report and a call for caution. Neuromuscular disorders : NMD. vol 26. issue 4-5. 2017-01-03. PMID:27012182. |
we report the first case report of worsening of myasthenia after receiving long-acting risperidone injection for schizophrenia in a 29-year-old female with both diseases. |
2017-01-03 |
2023-08-13 |
Not clear |
| Chi-Shin Wu, I-Chih Cheng, Jung Feng, Chun-Lin Che. Comparison of treatment effectiveness and medical costs for different long-acting injectable antipsychotics in patients with schizophrenia in Taiwan: A nationwide population-based cohort study. Schizophrenia research. vol 173. issue 1-2. 2017-01-02. PMID:26987938. |
to assess the comparative effectiveness and medical costs of five long-acting injectable (lai) antipsychotics, flupentixol, fluphenazine, haloperidol, risperidone, and clopentixol/zuclopentixol, in patients with schizophrenia. |
2017-01-02 |
2023-08-13 |
Not clear |
| Satoko Yamashita, Tsuyoshi Miyaoka, Michiharu Nagahama, Masa Ieda, Keiko Tsuchie, Rei Wake, Jun Horiguch. Treatment of Paroxysmal Perceptual Alteration in Catatonic Schizophrenia by Switching to Aripiprazole from Risperidone: A Case Report. Clinical schizophrenia & related psychoses. vol 10. issue 1. 2016-12-30. PMID:24047761. |
treatment of paroxysmal perceptual alteration in catatonic schizophrenia by switching to aripiprazole from risperidone: a case report. |
2016-12-30 |
2023-08-12 |
Not clear |
| Satoko Yamashita, Tsuyoshi Miyaoka, Michiharu Nagahama, Masa Ieda, Keiko Tsuchie, Rei Wake, Jun Horiguch. Treatment of Paroxysmal Perceptual Alteration in Catatonic Schizophrenia by Switching to Aripiprazole from Risperidone: A Case Report. Clinical schizophrenia & related psychoses. vol 10. issue 1. 2016-12-30. PMID:24047761. |
we present a case of ppa in catatonic schizophrenia that was successfully treated by switching to aripiprazole from risperidone. |
2016-12-30 |
2023-08-12 |
Not clear |
| Javier Quintero, Itziar Oyagüez, Beatriz González, Ignacio Cuervo-Arango, Ignacio García, Miguel Angel Casad. Cost-Minimisation Analysis of Paliperidone Palmitate Long-Acting Treatment versus Risperidone Long-Acting Treatment for Schizophrenia in Spain. Clinical drug investigation. vol 36. issue 6. 2016-12-30. PMID:27000061. |
cost-minimisation analysis of paliperidone palmitate long-acting treatment versus risperidone long-acting treatment for schizophrenia in spain. |
2016-12-30 |
2023-08-13 |
Not clear |
| William S Stone, Xiaolu Hsi, Anthony J Giuliano, Liwen Tan, Shaochun Zhu, Lingjiang Li, Larry J Seidman, Ming T Tsuan. Are neurocognitive, clinical and social dysfunctions in schizotaxia reversible pharmacologically?: Results from the Changsha study. Asian journal of psychiatry. vol 5. issue 1. 2016-12-13. PMID:22489255. |
the results are generally consistent with previous open-label investigations of risperidone administration in subjects with schizotaxia, and provide evidence that some neurocognitive and clinical problems are amenable to remediation in non-psychotic relatives of people with schizophrenia. |
2016-12-13 |
2023-08-12 |
human |
| Jakub Tomasik, Emanuel Schwarz, Santiago G Lago, Matthias Rothermundt, F Markus Leweke, Nico J M van Beveren, Paul C Guest, Hassan Rahmoune, Johann Steiner, Sabine Bah. Pretreatment levels of the fatty acid handling proteins H-FABP and CD36 predict response to olanzapine in recent-onset schizophrenia patients. Brain, behavior, and immunity. vol 52. 2016-12-13. PMID:26541453. |
here, we have attempted to identify candidate blood biomarkers associated with drug response in 121 initially antipsychotic-free recent-onset schizophrenia patients treated with widely-used antipsychotics, namely olanzapine (n=40), quetiapine (n=23), risperidone (n=30) and a mixture of these drugs (n=28). |
2016-12-13 |
2023-08-13 |
Not clear |
| Qi-Jing Bo, Xian-Bin Li, Zhi-Min Wang, An-Ning Li, Xin Ma, Chuan-Yue Wan. Extrapyramidal Symptoms During Risperidone Maintenance Treatment in Schizophrenia: A Prospective, Multicenter Study. Journal of clinical psychopharmacology. vol 36. issue 2. 2016-12-13. PMID:26848792. |
extrapyramidal symptoms during risperidone maintenance treatment in schizophrenia: a prospective, multicenter study. |
2016-12-13 |
2023-08-13 |
Not clear |
| Qi-Jing Bo, Xian-Bin Li, Zhi-Min Wang, An-Ning Li, Xin Ma, Chuan-Yue Wan. Extrapyramidal Symptoms During Risperidone Maintenance Treatment in Schizophrenia: A Prospective, Multicenter Study. Journal of clinical psychopharmacology. vol 36. issue 2. 2016-12-13. PMID:26848792. |
the risperidone maintenance treatment in schizophrenia study was designed to identify the duration of maintenance treatment required with an initial therapeutic dose in contrast to reducing the dose over time. |
2016-12-13 |
2023-08-13 |
Not clear |
| Negar Iranpour, Atefeh Zandifar, Mehdi Farokhnia, Amirhossein Goguol, Habibeh Yekehtaz, Mohammad-Reza Khodaie-Ardakani, Bahman Salehi, Sophia Esalatmanesh, Atefeh Zeionoddini, Payam Mohammadinejad, Arefeh Zeinoddini, Shahin Akhondzade. The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial. Human psychopharmacology. vol 31. issue 2. 2016-12-13. PMID:26856695. |
in this study, we evaluated the efficacy of pioglitazone as an adjunct to risperidone for reduction of negative symptoms in schizophrenia. |
2016-12-13 |
2023-08-13 |
Not clear |
| Azmi F Nasser, David C Henderson, Maurizio Fava, Paul J Fudala, Philip Twumasi-Ankrah, Alex Kouassi, Christian Heidbrede. Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study. Journal of clinical psychopharmacology. vol 36. issue 2. 2016-12-13. PMID:26862829. |
efficacy, safety, and tolerability of rbp-7000 once-monthly risperidone for the treatment of acute schizophrenia: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study. |
2016-12-13 |
2023-08-13 |
human |
| Yosuke Koshikawa, Yoshiteru Takekita, Masaki Kato, Shiho Sakai, Ai Onohara, Naotaka Sunada, Keiichiro Nishida, Masafumi Yoshimura, Chiara Fabbri, Alessandro Serretti, Toshihiko Kinoshit. The Comparative Effects of Risperidone Long-Acting Injection and Paliperidone Palmitate on Social Functioning in Schizophrenia: A 6-Month, Open-Label, Randomized Controlled Pilot Trial. Neuropsychobiology. vol 73. issue 1. 2016-11-07. PMID:26812618. |
the comparative effects of risperidone long-acting injection and paliperidone palmitate on social functioning in schizophrenia: a 6-month, open-label, randomized controlled pilot trial. |
2016-11-07 |
2023-08-13 |
Not clear |
| Yosuke Koshikawa, Yoshiteru Takekita, Masaki Kato, Shiho Sakai, Ai Onohara, Naotaka Sunada, Keiichiro Nishida, Masafumi Yoshimura, Chiara Fabbri, Alessandro Serretti, Toshihiko Kinoshit. The Comparative Effects of Risperidone Long-Acting Injection and Paliperidone Palmitate on Social Functioning in Schizophrenia: A 6-Month, Open-Label, Randomized Controlled Pilot Trial. Neuropsychobiology. vol 73. issue 1. 2016-11-07. PMID:26812618. |
the aim of this study was to compare the effects of risperidone long-acting injection (rlai) and paliperidone palmitate (pp) on non-acute-phase social functioning in patients with schizophrenia. |
2016-11-07 |
2023-08-13 |
Not clear |
| Zongchang Li, Maolin Hu, Xiaofen Zong, Ying He, Dong Wang, Lulin Dai, Min Dong, Jun Zhou, Hongbao Cao, Luxian Lv, Xiaogang Chen, Jinsong Tan. Association of telomere length and mitochondrial DNA copy number with risperidone treatment response in first-episode antipsychotic-naïve schizophrenia. Scientific reports. vol 5. 2016-11-01. PMID:26680692. |
association of telomere length and mitochondrial dna copy number with risperidone treatment response in first-episode antipsychotic-naïve schizophrenia. |
2016-11-01 |
2023-08-13 |
Not clear |
| Vesta Steibliene, Adomas Bunevicius, Arunas Savickas, Arthur J Prange, Charles B Nemeroff, Robertas Buneviciu. Triiodothyronine accelerates and enhances the antipsychotic effect of risperidone in acute schizophrenia. Journal of psychiatric research. vol 73. 2016-10-20. PMID:26679760. |
triiodothyronine accelerates and enhances the antipsychotic effect of risperidone in acute schizophrenia. |
2016-10-20 |
2023-08-13 |
Not clear |